文献速递艾滋病与性传播感染病毒性肝炎

HIV/HCV合并感染患者在临床实践中对格卡瑞韦/哌仑他韦的应答

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

研究基于HEPAVIR-DAA和GEHEP-MONO两个多中心队列,分析开始格卡瑞韦/哌仑他韦(G/P)治疗的可评估患者,比较HIV/HCV合并感染与HCV单一感染者的持续病毒学应答(SVR)。结果显示合并感染者总体SVR为126/132(95.5%),单一感染者为487/512(95.1%),两组8周或12周治疗的SVR相似,但活动性药物使用是合并感染者未达SVR的主要原因。

要点

  • HIV/HCV合并感染者G/P总体SVR为126/132(95.5%),与HCV单一感染者487/512(95.1%)相似。
  • 合并感染者中1例(0.8%)复发,1例(0.8%)因副作用停药。
  • 合并感染者未达SVR的主要原因是与活动性药物使用相关的提前脱落。

核心结论

  • G/P在临床实践中的HIV/HCV合并感染治疗高效且可耐受。
  • HIV/HCV合并感染者接受8周或12周G/P治疗的SVR与HCV单一感染者相似,但活动性药物使用仍是实现HCV微消除的障碍。

研究设计与样本

  • HEPAVIR-DAA队列(NCT02057003)招募HIV/HCV合并感染者,GEHEP-MONO队列(NCT02333292)纳入HCV单一感染者,两者为正在进行的多中心队列。
  • 分析两个队列中开始G/P治疗的患者,评估总体SVR(意向性治疗分析)、因不良反应停药和脱落,并在两队列间比较。

主要发现

  • 开始G/P治疗且SVR可评估的患者共644例,其中HIV/HCV合并感染者132例。
  • 总体SVR率:HCV单一感染者487/512(95.1%),HIV/HCV合并感染者126/132(95.5%),P=1.000。
  • HIV/HCV合并感染者中1例(0.8%)复发,1例(0.8%)因副作用停药。
  • HIV/HCV合并感染者与HCV单一感染者接受8周或12周G/P治疗的SVR相似。
  • HIV/HCV合并感染者未达SVR的主要原因是与活动性药物使用相关的提前脱落。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials. METHODS: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts. RESULTS: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use. CONCLUSIONS: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Serna A, Corma-Gomez A, Tellez F, et al. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice. J Antimicrob Chemother. 2023. PMID: 37671831. doi:10.1093/jac/dkad278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。